Get Our Top Trade Ideas Delivered Daily - 65% Off Now'
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now'
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Swedish Orphan Biovitrum
BIOVF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$24.07
0
0.00%
Last update: Aug 5, 1:08 PM
15 minutes delayed
Get Report
Comment
Swedish Orphan Biovitrum (BIOVF) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Swedish Orphan Biovitrum (OTC:BIOVF) Stock
Swedish Orphan Biovitrum Stock (OTC: BIOVF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, August 08, 2024
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Vandana Singh
Monday, October 16, 2023
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
Vandana Singh
Monday, June 26, 2023
Sanofi, Sobi Earlier Announced ALTIVIIIO Late-breaking Data At ISTH Demonstrates Highly Effective Bleed Protection In Children With Severe Hemophilia A With Once-weekly Dosing
Charles Gross
Friday, June 09, 2023
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
Vandana Singh
Thursday, May 25, 2023
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
Vandana Singh
Thursday, May 11, 2023
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Chris Katje
Wednesday, May 10, 2023
European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
Vandana Singh
Tuesday, March 21, 2023
Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
Vandana Singh
Thursday, November 10, 2022
Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
Shanthi Rexaline
Friday, November 04, 2022
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Vandana Singh
Tuesday, August 30, 2022
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
Vandana Singh
Monday, July 11, 2022
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Vandana Singh
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
Vandana Singh
Friday, July 08, 2022
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Vandana Singh
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
Vandana Singh
Wednesday, March 09, 2022
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Vandana Singh
Wednesday, December 15, 2021
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
Vandana Singh
Friday, December 03, 2021
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
Vandana Singh
Wednesday, February 24, 2021
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021
Benzinga Insights
Barclays Downgrades Swedish Orphan Biovitrum ...
Benzinga Newsdesk
Tuesday, July 28, 2020
Sobi and Selecta Announce Closing of Previously Announced Strategic Licensing Agreement for Sel-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout
Charles Gross
Thursday, October 03, 2019
Stocks That Hit 52-Week Lows On Thursday
Lisa Levin
Monday, August 26, 2019
Stocks That Hit 52-Week Lows On Monday
Lisa Levin
Sunday, December 10, 2017
Bioverativ and Swedish Orphan Biovitrum AB Announc Study Shows Weekly Prophylactic Treatment with ELOCTATE Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A at #ASH2017
Benzinga
Friday, May 13, 2016
Biogen, Swedish Orphan Biovitrum Announce EC Approves Alprolix for Treatment of Haemophilia B
Benzinga
Friday, October 16, 2015
Swedish Orphan Biovitrum AB Announces Approval of Xiapex by Swissmedic for Treatment of Peyronie's disease in Switzerland
Benzinga
Monday, December 22, 2014
Sobi, Auxilium Announce Xiapex Receives Positive Opinion by CHMP for Treatment of Peyronie's Disease
Benzinga